
🚨 Our work exploring polygenic risk scores for Coronary Heart Disease is now out in @JAMA_current and presented at #AHA24 by all-star @SarnoffCardio fellow @sabramowitz_: jamanetwork.com/journals/jam…

🫀🧬 Cardiologist and genetic epidemiologist @PennCardiology and @VAPhiladelphia focused on translating human genetic insights into better cardiovascular care

🚨 Our work exploring polygenic risk scores for Coronary Heart Disease is now out in @JAMA_current and presented at #AHA24 by all-star @SarnoffCardio fellow @sabramowitz_: jamanetwork.com/journals/jam…

In @JAMA_current, we report that a single African ancestry-enriched CD36 variant (Y325*) contributes more to the population burden of dilated cardiomyopathy (DCM) in individuals of African ancestry than TTN truncating variants or other known DCM genes. ja.ma/3Wy9k40

Very excited to share our preprint led by @MGLevin @skoyamamd @jakob_woerner & with @damrauer assessing genome-wide pleiotropy of >1,000 clinical traits across ~1.7M individuals with nearly 30K locus-trait associations! medrxiv.org/content/10.1101/… @medrxivpreprint [1/3]

CVI's Highlighted #PapersoftheWeek rdcu.be/egHer

Common-variant and rare-variant genetic architecture of heart failure across the allele-frequency spectrum | @NatureGenet nature.com/articles/s41588-0…

Check out this editorial just published in @JAMACardio by our very own💫@PennCardiology fellow Anthony Anguiera & @sabramowitz_ under the mentorship of the one & only @MGLevin! Unfolding the Link Between Transthyretin Stability and Survival jamanetwork.com/journals/jam…

CVI's Highlighted #PapersoftheWeek @MGLevin doi.org/10.1001/jama.2024.23…

New research by @damrauer & @MGLevin suggests that polygenic risk scores may provide conflicting results for detecting heart disease risk. spr.ly/6018scAup

Now out in @JAMA_current: How well do individual risk estimates from different CHD polygenic scores agree? Grateful to work on this with a dream team of mentors and co-authors @damrauer @MGLevin @bpasaniuc @MarylynRitchie @dokyoon_kim @bvoight28 @BoulierKristin @karlkeat
🚨 Our work exploring polygenic risk scores for Coronary Heart Disease is now out in @JAMA_current and presented at #AHA24 by all-star @SarnoffCardio fellow @sabramowitz_: jamanetwork.com/journals/jam…

14/ To learn more, - Check out this editorial: jamanetwork.com/journals/jam… - Listen to this AI-generated podcast summary: notebooklm.google.com/notebo…

13/ It was fun working with the team: @sabramowitz_, @damrauer, @BoulierKristin, @karlkeat, @MarylynRitchie, @bvoight28, @bpasaniuc and everyone else. More exciting work to come!

12/ Overall, we need better frameworks for evaluating PRS at both the individual and population level, and approaches for dealing with the variability/uncertainty if PRS are going to become clinically useful.

11/ These results don't address other uses of PRS where individual-level performance may be less critical (eg. population-health, enriching the average risk of a clinical trial cohort, etc.).

10/ Our findings raise important practical questions about the implementation of PRS: - When PRS from two different sources disagree, which should we believe? - How should we counsel patients about uncertainty? - Can CAD PRS be individually useful given these limitations?

9/ Explore how these CAD PRS vary for yourself: mglev1n.github.io/CAD-prs-va…

8/ Concerningly, ~20% of participants had at least one score in both the top 5% and bottom 5%, and ~80% had at least one score in the top/bottom 20%.